German drugmaker Biotest turns back on Greece: CFO

FRANKFURT (Reuters) – German drugmaker Biotest said it is exiting the Greek market in July after its customers there failed to pay their bills, according to a newspaper interview.

“We told the Greek health ministry in April that we would exit the market within three months if no payments were made,” Biotest’s Chief Financial Officer Michael Ramroth told Boersen-Zeitung in an interview published on Saturday.

“And I don’t believe that manna will fall from heaven in June.”

Greece has failed to dig its way out of a deep economic crisis and has left unpaid many bills sent to state-run hospitals for the delivery of drugs and medical supplies.

Major drugmakers such as Bayer, Merck KGaA and Fresenius have said they would continue to supply Greece, which relies heavily on medical supplies imported from other countries.

Biotest’s Ramroth said Greece had paid all its outstanding bills for 2010 but still owed the company 7 million euros ($8.8 million) for 2011.

“Payments for the latest receivables have been extremely slow,” he said.

Biotest, which makes plasma proteins and monoclonal antibodies, generated revenue of 422 million euros in 2011.

Finance chief Ramroth said he had not seen any deterioration of business in Italy so far.

“But we are prepared in Italy and could sell receivables, such contracts are already wrapped up with banks,” he said.

Ramroth also said Biotest could spend as much as 300 million euros on acquisitions.

($1 = 0.7921 euros)

(Reporting by Maria Sheahan; Editing by John Stonestreet)

Views: 0

You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

Powered by WordPress | Designed by: Premium WordPress Themes | Thanks to Themes Gallery, Bromoney and Wordpress Themes